Bioniche Announces Reorganization of Leadership Team

-move to increase efficiency and better position Company for strategic growth-

BELLEVILLE, ON, Jan. 3 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced a reorganization of its corporate leadership team with a goal of increasing efficiency and better positioning the Company for strategic growth. This reorganization takes effect immediately.

Bioniche Animal Health Leadership

In the Bioniche Animal Health business unit, Jim Phillips, President of Bioniche Animal Health (global) has taken on a new role as Senior Vice-President, Industry Relations. This is a strategic position that will enable the Company to be more proactive in its pursuit of potential product and technology acquisitions, as well as to be more engaged with the veterinarian community as a whole, the customers of Bioniche Animal Health. Jim has been with Bioniche for 25 years, and is well-known in the animal health industry in North America and beyond. He has provided strong leadership to the Animal Health division and will continue to grow the Company's animal health business in this new portfolio.

Andrew Grant, Divisional President of Bioniche Animal Health Export Sales, Europe and A/Asia, has been promoted to President of Bioniche Animal Health (global). Andrew has been with the Company for 12 years, starting as Managing Director of Bioniche Animal Health A/Asia. He has a broad depth of knowledge of the industry and an excellent awareness of potential future growth opportunities for the business.

Bioniche Human Health Clinical Leadership

In the Company's Human Health business unit, Dr. François Charette, Senior Vice-President of Medical Affairs and Chief Medical Officer, has left Bioniche to pursue new career opportunities. The Medical Affairs group is now under the leadership of Monique Champagne, Vice-President, Clinical Research. In this role, Monique will be working with the Human Health team to identify and pursue new human health indications for the Company's core proprietary Mycobacterial Cell Wall-DNA Complex (MCC) technology. Monique joined the Company as Director, Clinical Research in 2006.

"Having successfully concluded an equity financing in December, the Company is poised with the financial resources it requires to more efficiently advance a number of its key strategic projects," said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc. "At the same time, we must ensure that we have the appropriate people in key leadership positions to take advantage of the opportunities in front of us. I believe that the administrative reorganization achieves this objective."

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs 217 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.